Key result
Half-dose alteplase resolves right atrial thrombus in COVID-19 within 4 days.
Why the study?
COVID-19 is strongly associated with pro-thrombotic states, but management of right atrial thrombus in COVID-19 patients is not well described.
Case Report (n=1)
No
Single-case success with half-dose anticoagulation for right atrial thrombus in COVID-19; leaves open efficacy versus full-dose regimens in broader populations.
Coronavirus disease 2019 (COVID-19) is a worldwide pandemic. Evidence suggests a strong association between COVID-19 and pro-thrombotic states. We report our experience in managing a patient with COVID-19 complicated by a right atrial thrombus. We highlight the successful use of half-dose anticoagulation in the treatment of right atrial thrombus in a patient with COVID-19. To our knowledge, this is a first reported case of right atrial thrombus in a COVID-19 patient who was treated successfully with half-dose anticoagulation.
No takes yet. Share an insight, caveat, or question.
Terrigno et al. (2020) conducted a case report in COVID-19 with right atrial thrombus (n=1). Alteplase was evaluated on Resolution of right atrial thrombus. Administration of half-dose alteplase (50 mg) successfully resolved a right atrial thrombus in a 76-year-old woman with COVID-19 by day 4.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: